

|                  |                                                                  |
|------------------|------------------------------------------------------------------|
| Name of Assessee | : <b>M S Medicals Pvt Ltd</b>                                    |
| Address          | LG 2A, Mohan Bazar, Central Market<br>Ashok Vihar, Delhi -110052 |
| PAN              | : AAFCM4774M                                                     |
| Assessment Year  | : 2025-26                                                        |
| Status           | : Private Limited Company                                        |

### Computation of Income

| Particulars                              |           | Amount (Rs.)     |
|------------------------------------------|-----------|------------------|
| <b>Income from Business</b>              |           |                  |
| Net Profit as per Profit & Loss Account  |           | 85,84,949        |
| Add: Depreciation as per Companies Act   | 20,88,423 |                  |
| Provision for Gratuity                   | 14,38,860 |                  |
| Provision for Leave Encashment           | 3,35,418  |                  |
| Donation                                 | 50,000    |                  |
| Diallowed -Late Payment MSME             | 4,15,307  |                  |
| Late Deposit of ESI                      | 25,886    |                  |
|                                          |           | <u>43,53,894</u> |
|                                          |           | 1,29,38,843      |
| Less: Depreciation as per Income Tax Act | 8,73,869  |                  |
| Profit on Sale of Fixed Assets           | 7,66,806  |                  |
|                                          |           | <u>16,40,675</u> |
| <b>Gross Profit</b>                      |           | 1,12,98,168      |
| <b>Taxable Income</b>                    |           | 1,12,98,168      |
| Tax Due                                  |           | 24,85,597        |
| Surcharge @10%                           |           | 2,48,560         |
|                                          |           | <b>27,34,157</b> |
| Add: Education Cess 4%                   |           | <u>1,09,366</u>  |
|                                          |           | 28,43,526        |
| Add: Interest                            |           | <u>2,97,294</u>  |
|                                          |           | 31,40,819        |
| Less: TDS & Advance Tax                  | 402449    |                  |
| Self Assessment                          | 27,38,370 |                  |
|                                          |           | <u>31,40,819</u> |
| <b>Tax Payable</b>                       |           | <u><u>-</u></u>  |



***RGMG & CO.***

CHARTERED ACCOUNTANTS  
120, Rajendra Bhawan, Rajendra Place,  
New Delhi-110 008 Phone : (91)-(11) 2576 1681  
Email : rajesh@rgmg.org, manoj@rgmg.org

## INDEPENDENT AUDITORS' REPORT

To, The Members  
M S Medicals Private Limited

### Report on the Standalone Financial Statements

#### Opinion

We have audited the accompanying standalone financial statements of **M S Medicals Private Limited** ("the Company"), which comprise the Balance Sheet as at 31st March, 2025, and the Statement of Profit and Loss for the year then ended, and notes to the financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2025, and profit for the year ended on that date.

#### Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. *Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report.* We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the Standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.



### **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

### **Information other than the financial statements and auditors' report thereon**

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual report, but does not include the standalone financial statements and our auditor's report thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Management's Responsibility for the Standalone Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company



and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### **Auditor's Responsibilities for the Audit of the Standalone Financial Statements**

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a



material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedure that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls systems in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to



communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### **Report on Other Legal and Regulatory Requirements**

1. Being a small Company, the provisions of the Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government in terms of section 143(11) of the Act is not applicable to the Company.
2. As required by Section 143 (3) of the Act, we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.
  - d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as amended.
  - e) On the basis of the written representations received from the directors as on 31st March, 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
  - f) Since the Company's turnover as per last audited financial statements is less



than Rs. 50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs 25 Crore, the Company is exempted from getting an audit opinion with respect to the adequacy of the financial controls over financial reporting of the Company and the operating effectiveness of such controls vide notification dated June 13, 2017; and

g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. The Company does not have any pending litigations which would impact its financial position.
- ii. The company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
- iv. a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;  
b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding,




whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

c) Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material mis-statement.

- v. The company has not declared or paid dividend during the year.
- vi.. Based on our examination which included test checks the Company has used accounting software maintaining its books of account, which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the respective software. Further, for the periods where audit trail (Edit Log) facility was enabled and operated throughout the year for the respective accounting software, we did not come across any instance of the audit trail feature being tampered with.

For RGMG & CO.  
Chartered Accountants  
FRN No. 006329N



**Rajesh Gupta**

Partner

Membership No. 096116

Place: New Delhi

Date: 16.07.2025

UDIN: 25096737BMMJJ13639



**M S Medicals Private Limited**  
**Balance Sheet as at 31st March, 2025**

(In Rs.,000)

| Particulars                      | Note No | 2025            | 2024            |
|----------------------------------|---------|-----------------|-----------------|
| <b>I. EQUITY AND LIABILITIES</b> |         |                 |                 |
| <b>Shareholders' funds</b>       |         |                 |                 |
| Share Capital                    | 2       | 9540.00         | 9540.00         |
| Reserve and surplus              | 3       | 32030.31        | 26404.97        |
| <b>Non-current liabilities</b>   |         |                 |                 |
| Long-term borrowings             | 4       | 3552.59         | 8136.97         |
| Other Non Current Liabilities    | 5       | -               | 150.00          |
| Long-term Provisions             | 6       | 1717.68         | -               |
| <b>Current liabilities</b>       |         |                 |                 |
| Short-term borrowings            | 7       | 27095.18        | 26161.79        |
| Trade payables                   | 8       | 10029.50        | 14078.32        |
| Other current liabilities        | 9       | 5292.74         | 2431.40         |
| Current Provisions               | 10      | 2806.60         | -               |
| <b>TOTAL</b>                     |         | <b>92064.61</b> | <b>86903.44</b> |
| <b>II. ASSETS</b>                |         |                 |                 |
| <b>Non-current assets</b>        |         |                 |                 |
| Property, Plant and Equipment    | 11      | 5799.87         | 6857.43         |
| Deferred tax assets(Net)         | 12      | 223.07          | 432.68          |
| Long-term loans and advances     | 13      | 1289.90         | 1294.21         |
| <b>Current assets</b>            |         |                 |                 |
| Inventories                      | 14      | 18168.14        | 13027.03        |
| Trade receivable                 | 15      | 59919.25        | 55215.94        |
| Cash and cash equivalents        | 16      | 5309.87         | 7472.33         |
| Short-term loans and advances    | 17      | 503.47          | 2410.57         |
| Other current assets             | 18      | 851.03          | 193.25          |
| <b>TOTAL</b>                     |         | <b>92064.61</b> | <b>86903.44</b> |

The accompanying notes form an integral part of financial statement.

As per our report of even date

For RGMG & CO.

Firm Regd No. 06329N

Chartered Accountants



**Rajesh Gupta**

Partner

M.No. 096737

New Delhi

For and on behalf of the Board

  
**Sanjay Manocha**  
 Director  
 DIN:00076997

  
**Yogesh Sachdeva**  
 Director  
 DIN: 00077095

  
**Kartik Palta**  
 Director  
 DIN: 01543913

  
**Sukesh Arora**  
 Director  
 DIN: 10682240



**M S Medicals Private Limited**  
**Statement of Profit & Loss for the year ended 31st March 2025**

(In Rs.,000)

|     | Particulars                                  | Note No | 2025             | 2024             |
|-----|----------------------------------------------|---------|------------------|------------------|
|     | <b>Income:</b>                               |         |                  |                  |
| I   | Revenue from operations                      | 19      | 240233.85        | 195382.48        |
|     | Other income                                 | 20      | 1033.19          | 293.86           |
|     | <b>Total Income (I+II)</b>                   |         | <b>241267.04</b> | <b>195676.34</b> |
| II  | <b>Expenses:</b>                             |         |                  |                  |
|     | Purchase of Stock-in-Trade                   | 21      | 191612.05        | 148831.25        |
|     | Change in inventories of Stock               | 22      | -5141.11         | 4490.65          |
|     | Employee benefits expenses                   | 23      | 20420.21         | 18550.76         |
|     | Finance costs                                | 24      | 3600.96          | 4196.34          |
|     | Depreciation and amortization exp.           | 25      | 2088.42          | 722.60           |
|     | Other Expenses                               | 26      | 20101.56         | 17536.00         |
|     | <b>Total expenses</b>                        |         | <b>232682.09</b> | <b>194327.60</b> |
| III | <b>Profit before tax (I-II)</b>              |         | 8584.95          | 1348.74          |
| IV  | <b>Tax expenses:</b>                         |         |                  |                  |
|     | Current Tax                                  |         | 2750.00          | 184.18           |
|     | Deferred Tax                                 |         | 209.61           | 335.76           |
| V   | <b>Profit (Loss) for the period (III-IV)</b> |         | 5625.34          | 828.80           |
| VI  | <b>Earning per equity share:</b>             |         |                  |                  |
|     | Basic & Diluted                              |         | 5.90             | 0.87             |

The accompanying notes form an integral part of financial statement.

As per our report of even date

For RGMG & CO.  
Firm Regd No. 06329N  
Chartered Accountants

**Rajesh Gupta**  
Partner  
M.No. 096737  
New Delhi



For and on behalf of the Board

**Sanjay Manocha**  
Director  
DIN:00076997

**Yogesh Sachdeva**  
Director  
DIN: 00077095

**Kartik Palta**  
Director  
DIN: 01543913

**Sukesh Arora**  
Director  
DIN: 10682240

**Notes forming part of the Financial Statements for the year ended March 31,2025**

**1 Corporate Information**

M.S.Medicals Private Limited . ("the Company") had its origin in the year 2003 as partnership firm named "M.S.Medicals". In the year 2008, the firm was converted into a Company with the objective of engaged was incorporated at Delhi on 24th March, 2008 under the Companies Act, 1956. At present the Registered Office of the company is LG--2A, Mohan Bazar, Central Market, Ashok Vihar-I, Delhi-110052. The company engaged in the business of all type of medicines, surgical items, surgical equipment's, medical preparations, Surgicals disposable goods, pathological and laboratory items and other related chemicals and goods.

**2 Significant Accounting Policies**

**2.1 Basis of accounting and preparation of financial statements**

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principal in India (Indian GAAP) to comply with the Accounting Standards notified under the Companies (Accounting Standard) Rules, 2006 (as amended) and the relevant provisions of the Companies Act, 1956. The financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.

**2.2 Use of estimates**

The preparation of financial statements in conformity with Indian GAAP requires the Management to make estimate and assumptions considered in the reported amount of assets and liabilities (including contingent liabilities) and the reported income and expenses during the year. The Management believe that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the difference between the actual results and the estimates are recognised in

**2.3 Inventories**

Inventories are valued at the lower of cost and the net realisable value after providing for obsolescence and other losses, where considered necessary. Cost includes all charges in bringing the goods to the point of sale.

**2.4 Cash and cash equivalents**

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short term, highly liquid investment that are readily convertible into known amount of cash and which are subject to insignificant



## **2.5 Depreciation and amortisation**

Depreciation on Fixed Assets is provided on a Written down value method, over the estimated useful life of the Assets in the manner prescribed in Schedule II of the Act.

## **2.6 Revenue recognition**

Revenues/Incomes and Costs/Expenditure are generally accounted on accrual, as they are earned or incurred. Sale of goods is recognised on transfer of significant risks and rewards of ownership which is generally on the dispatch of goods.

## **2.7 Tangible Fixed Assets**

Fixed Assets are carried at cost less accumulated depreciation and impairment loss, if any. The cost of fixed assets includes cost of purchase and other incidental cost of purchase and other incidental expenses incurred up to the date the asset is ready for its intended use. Subsequent expenditure relating to fixed assets is capitalised only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

Fixed Assets acquired in full or part exchange for another assets are recorded at the fair market value or the net market value of the assets given up, adjusted or any balancing cash consideration. Fair market value is determined either for the assets acquired or assets given up, whichever is more clearly evident.

Fixed assets retired from active use and held for sale are stated at the lower of their net book value and net realisable value, and are disclosed separately in the Balance Sheet.

Capital work-in-progress: Projects under which assets are not ready for their intended use and other capital work-in-progress are carried at cost comprising direct cost and related incidental expenses.

## **2.8 Intangible Assets**

Intangible assets are carried at cost less accumulated amortisation and impairment losses, if any. The cost of an intangible asset comprises its purchase price, including any import assets and other taxes (other than those subsequently recoverable from the taxing authorities), and any directly attributable expenditure on making the asset ready for its intended use and net of any trade discounts and rebates. Subsequent expenditure on an intangible assets after its purchase / completion is recognised as an expenses when incurred unless it is probable that such expenditure will enable the asset to generate future economic benefits in excess of its originally assessed standards of performance and such expenditure can be measured and attributed to the assets reliably, in which case such expenditure is added to the cost of the assets.



## 2.9 Foreign currency transactions and translations

Initial recognition: Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.

Measurement of foreign currency monetary items at the Balance Sheet date: Foreign currency monetary items outstanding at the Balance Sheet date are restated at the year end rates.

Treatment of exchange differences: Exchange difference arising on settlement/ restatement of foreign currency monetary assets and liabilities of the Company are recognised as income or expenses in the Statement of Profit & Loss.

## 2.10 Investments

Long-term investment are carried individually at cost less provision for diminution, other than temporary, in the value of such investment. Current investment are carried individually, at the lower of cost and fair value. Cost of investments includes acquisition charges such as brokerage, fees and duties.

## 2.11 Note on Provision for Gratuity and Leave Encashment

The Company had not made any provision towards gratuity and leave encashment liability in the earlier years since its incorporation. During the financial year 2024-25, the Company has obtained an actuarial valuation of gratuity and leave encashment liability from a registered valuer in accordance with the requirements of Accounting Standard (AS) 15 "Employee Benefits".

The Company had not made any provision towards gratuity and leave encashment liability in the earlier years since its incorporation. During the financial year 2024-25, the Company has obtained an actuarial valuation of gratuity and leave encashment liability from a registered valuer in accordance with the requirements of Accounting Standard (AS) 15 "Employee Benefits".

Based on the actuarial valuation as at March 31, 2025, the following provisions have been recognized in the financial statements for the first time:

**Gratuity Liability:** Rs. 14,38,860

**Leave Encashment Liability:** Rs. 3,35,418

Accordingly, the total provision of Rs.17,74,278 has been created and charged to the Statement of Profit and Loss for the year ended March 31, 2025.

Management believes that the recognition of such liabilities in the current year appropriately represents the Company's obligation towards its employees as at the balance sheet date.

## 2.12 Borrowing Costs

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets. A qualifying



asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charged to Profit & Loss Account.

### **2.13 Segment reporting**

The Group identifies primary segment based on the dominant source, nature of risks and returns and the internal organisation and management structure. The operating segments are the segments for which separate financial information is available and for which operating profit /loss amounts are evaluated regularly by the executive Management in deciding how to allocate resources and in assessing performance.

The Company is engaged in trading of Medicine, Surgical Items and related medical items. As the revenue comes only from one activity so that the segment reporting is not required.



#### **2.14 Leases**

The Company has not entered into any Lease Transaction.

#### **2.15 Earning Per Share**

Basic Earning per Share is computed by dividing Profit / (loss) for the year by the weighted average number of equity shares outstanding during the year. Diluted earning per share is computed by dividing the profit / (loss) for the year as adjusted for dividend, interest and other charges to expenses or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares.

#### **2.16 Taxes on Income**

Current tax is determined in the basis of taxable income and tax credits computed for each of the entities in the Group in accordance with the provisions of applicable tax laws of the respective jurisdictions where the entities are located.

Deferred tax is recognised on timing difference between taxable income and the accounting income the originate in one period and are capable of reversal in one or more subsequent periods. Deferred tax is measured using the tax rates and the tax laws enacted or subsequently enacted as at the reporting date. Deferred tax liabilities are recognised for all timing differences. Current and deferred tax relating to items directly recognised in reserves are recognised in reserves and not in the Statement of Profit and Loss.

#### **2.17 Impairment of assets**

The carrying value of assets/ cash generating units at each Balance Sheet date are reviewed for impairment. If any indication of impairment exists, the recoverable amount of such assets is estimated and impairment is recognised, if the carrying amount of these assets exceeds their recoverable amount. The recoverable amount is greater of the net selling price and their value in use. Value in use is arrived at by discounting the future cash flow to their present value based on an appropriate discount factor. When there is indication the an impairment loss recognised for an asset in earlier accounting periods no longer exists or may have decreased, such reversal of impairment loss is recognised in the Statement of Profit & Loss, except in case of revalued assets.

#### **2.18 Provisions, Contingent Liabilities and Contingent Assets**

Provisions involving substantial degree of estimation in measurement are recognized when there is present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognised but are disclosed in the notes. Contingent Assets are neither recognized nor disclosed in the financial statements.



**2.19** The MCA Vide Notification dated 24th March 2021 has amended Schedule III to the Companies Act, 2013 in respect of certain disclosures are applicable from 1st April, 2021. The Company incorporated the changes as per the said

- (I) The Companies has no transactions with Companies Struck off under section 248 of the Companies Act, 2013 or Section 560 of the Companies Act, 1956 during the year
- (ii) The Company has not traded or invested in Crypto Currency or Virtual Currency during the year.
- (iii) The Company do not have any Benami property, where any proceeding has been initiated or pending against the company for holding any Benami Property.
- (iv) The Company do not have any charge or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (v) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the intermediary shall:
  - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
  - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- (vi) The Company have not received any funds from any person(s) or entity(ies). Including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
  - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
  - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- (vii) The Company does not have any loans and advances in the nature of loans to promoters, directors, KMP and other related parties.

**2.20 Additional Information:**

| Particulars                                                       | In Rs.,000 |           |
|-------------------------------------------------------------------|------------|-----------|
|                                                                   | 31.03.25   | 31.03.24  |
| 1 Value of Imports                                                | 4,81.154   | 2,76.280  |
| 2 Expenditure in Foreign Currency                                 |            |           |
| -Outward Remittance                                               | 4,68.706   |           |
| - Travel Expenditure                                              | --         | --        |
| 3 Consumption of imported Raw Material components and spare parts | --         | --        |
| 4 Earning in foreign Currency                                     | 58,93.844  | 53,66.509 |
| 5 Amount remitted in foreign currency towards Dividend            | --         | --        |



## 2.21 Related Party Transaction

Following are the related parties and transactions made with them during the year.

- Key Management Personnel (KMP)  
Mr. Sanjay Manocha  
Mr. Yogesh Sachdeva  
Mrs. Archana Manocha  
Mrs. Mona Sachdeva
- Entities in which KMP/Relatives of KMP can exercise Significant influences  
Sceptre Medical Devices Private Limited  
Sceptre Medical (India) Private Limited  
Manya Sachdeva - Director's Daughter
- Detail of related party transactions during the year ended 31 March, 2025 and outstanding balance as at 31 March, 2025

|                                                   |            | (In Rs.,000) |
|---------------------------------------------------|------------|--------------|
|                                                   | 2025       | 2024         |
| <b>Remuneration</b>                               |            |              |
| Yogesh Sachdeva                                   | 900.00     | 1200.00      |
| Mona Sachdeva                                     | 1247.50    | 2610.00      |
| Manya Sachdeva                                    | 1305.00    | 1200.00      |
| Sanjay Manocha                                    | -          | 100.00       |
| Sukesh Arora                                      | 880.00     | -            |
| Kartik Palta                                      | 210.00     | -            |
| <b>Rent</b>                                       |            |              |
| Mrs Archana Manocha                               | 256.50     | 396.00       |
| Mrs Mona Sachdeva                                 | 256.50     | 396.00       |
| <b>Purchase of Goods</b>                          |            |              |
| Sceptre Medical Devices Private Limited           | 47340.24   | 43620.76     |
| Sceptre Medical (India) Private Limited           | 86122.63   | 71672.27     |
| <b>Sale of Goods</b>                              |            |              |
| Sceptre Medical Devices Private Limited           | 4111.80    | 2310.30      |
| Sceptre Medical (India) Private Limited           | -          | 703.00       |
| <b>Balance Outstanding at the end of the Year</b> |            |              |
| Sceptre Medical Devices Private Limited           | CR 1823.08 | 5695.01 CR   |
| Sceptre Medical (India) Private Limited           | DR 206.07  | 8301.30 CR   |

## 2.22 Detail of Current Maturities of Long Term Borrowings as below:

|                      | Long Term | Short Term | Total   |
|----------------------|-----------|------------|---------|
| 1 Secured Loans      |           |            |         |
| 2 HDFC Bank-Business | 339.17    | 1869.82    | 2208.99 |
| 3 HDFC Bank-Vehicle  | 1959.21   | 543.84     | 2503.05 |
| 4 Deutsche Bank      | 446.87    | 456.28     | 903.14  |
| 5 Axis Bank          | 360.13    | 276.31     | 636.44  |
| 6 ECEL Loan          | 447.22    | 501.17     | 948.39  |
| 7                    | 3552.59   | 3647.42    | 7200.01 |



2.23 Key Financial Ratios are as below:

In '000

| Sr.No | Ratio                               | Current Year |                   | Previous Year |                   | % Variance |
|-------|-------------------------------------|--------------|-------------------|---------------|-------------------|------------|
|       |                                     | Numerator    | Denominator Ratio | Numerator     | Denominator Ratio |            |
| 1     | Current Ratio                       |              |                   |               |                   |            |
|       | Current Assets                      |              |                   |               |                   |            |
|       | Current Liabilities                 |              |                   |               |                   |            |
|       | Current Assets                      |              |                   |               |                   |            |
|       | Inventories                         | 18168.14     |                   | 13027.03      |                   |            |
|       | Trade receivable                    | 59919.25     |                   | 55215.94      |                   |            |
|       | Cash and cash equivalents           | 5309.87      |                   | 7472.33       |                   |            |
|       | Short-term loans and advances       | 503.47       |                   | 2410.57       |                   |            |
|       | Other Current Assets                | 851.03       |                   | 193.25        |                   |            |
|       | Total                               | 84751.76     |                   | 78319.12      |                   |            |
|       | Current Liabilities                 |              |                   |               |                   |            |
|       | Trade payables                      |              | 10029.50          |               | 14078.32          |            |
|       | Short Term Loans                    |              | 27095.18          |               | 26161.79          |            |
|       | Other current liabilities           |              | 5292.74           |               | 2431.40           |            |
|       | Provision for Taxation              |              | 2806.60           |               | -                 |            |
|       | Total                               |              | 45224.02          |               | 42671.50          | 1.84       |
| 2     | Debt-Equity Ratio                   |              |                   |               |                   |            |
|       | Total Debts                         |              |                   |               |                   |            |
|       | Shareholders Equity                 |              |                   |               |                   |            |
|       | Debts                               |              |                   |               |                   |            |
|       | Long-term borrowings                | 3552.59      |                   | 8136.97       |                   |            |
|       | Short-term borrowings               | 27095.18     |                   | 26161.79      |                   |            |
|       |                                     | 30647.77     |                   | 34298.76      |                   |            |
|       | Shareholders Equity                 |              |                   |               |                   |            |
|       | Share Capital                       |              | 9540.00           |               | 9540.00           |            |
|       | Reserve and surplus                 |              | 32030.31          |               | 26404.97          |            |
|       |                                     |              | 41570.31          |               | 35944.97          | 0.95       |
| 3     | Debt Service Coverage Ratio         |              |                   |               |                   |            |
|       | Earning available for debts service |              |                   |               |                   |            |
|       | Debts Service                       |              |                   |               |                   |            |
|       | Earning for Debts Services          |              |                   |               |                   |            |
|       | Net Profit before Taxes             | 8584.95      |                   | 1348.74       |                   |            |
|       | Add: Depreciation                   | 2088.42      |                   | 722.60        |                   |            |
|       | Interest                            | 3600.96      |                   | 4196.34       |                   |            |
|       | Total                               | 14274.33     |                   | 6267.69       |                   |            |
|       | Debts Service                       |              |                   |               |                   |            |
|       | Interest Payment                    |              | 3600.96           |               | 4196.34           |            |
|       | Principal =Short Term & Long -term  |              | 4964.53           |               | 3583.64           |            |
|       |                                     |              | 8565.49           |               | 7779.98           | 0.81       |
| 4     | Return on Equity Ratio              |              |                   |               |                   |            |
|       | Net Profit after Taxes              |              |                   |               |                   |            |
|       | Shareholder Equity                  |              |                   |               |                   |            |
|       | Net Profit After Tax                | 5625.34      |                   | 828.80        |                   |            |
|       |                                     | 5625.34      |                   | 828.80        |                   |            |
|       | Shareholders Equity                 |              |                   |               |                   |            |



|   |                                        |           |         |           |       |        |
|---|----------------------------------------|-----------|---------|-----------|-------|--------|
|   | Share Capital                          | 9540.00   |         | 9540.00   |       |        |
|   | Reserve and surplus                    | 32030.31  |         | 26404.97  |       |        |
|   |                                        | 41570.31  | 0.14    | 35944.97  | 0.023 | 486.88 |
| 5 | <b>Inventory Turnover Ratio</b>        |           |         |           |       |        |
|   | Cost of Goods Sold/Sales               |           |         |           |       |        |
|   | Average Turnover                       |           |         |           |       |        |
|   | Sales                                  | 240233.85 |         | 195382.48 |       |        |
|   | Total                                  | 240233.85 |         | 195382.48 |       |        |
|   | Average Turnover                       |           |         |           |       |        |
|   | Opening Stock                          | 13027.03  |         | 17517.68  |       |        |
|   | Closing Stock                          | 18168.14  |         | 13027.03  |       |        |
|   | Total                                  | 31195.17  |         | 30544.71  |       |        |
|   | Average Turnover                       | 15597.59  | 15.40   | 15272.36  | 12.79 | 20.39  |
| 6 | <b>Trade Receivable Turnover Ratio</b> |           |         |           |       |        |
|   | Net Credit Sales                       |           |         |           |       |        |
|   | Average Accounts Receivable            |           |         |           |       |        |
|   | Net Credit Sales                       |           |         |           |       |        |
|   | Sales less Sales Return                | 240233.85 |         | 195382.48 |       |        |
|   |                                        | 240233.85 |         | 195382.48 |       |        |
|   | Average Account Receivable             |           |         |           |       |        |
|   | Opening Balance                        | 55215.94  |         | 56190.39  |       |        |
|   | Closing Balance                        | 59919.25  |         | 55215.94  |       |        |
|   | Average Account Receivable             | 57567.59  | 4.17307 | 55703.16  | 3.51  | 18.97  |
| 7 | <b>Trade Payable Turnover Ratio</b>    |           |         |           |       |        |
|   | Net Credit Purchases                   |           |         |           |       |        |
|   | Average Accounts Payable               |           |         |           |       |        |
|   | Net Credit Purchases                   |           |         |           |       |        |
|   | Purchases less Purchases Return        | 191612.05 |         | 148831.25 |       |        |
|   | Total                                  | 191612.05 |         | 148831.25 |       |        |
|   | Average Account Payable                |           |         |           |       |        |
|   | Opening Balance                        | 14078.32  |         | 20343.76  |       |        |
|   | Closing Balance                        | 10029.50  |         | 14078.32  |       |        |
|   | Average Account Payable                | 24107.82  |         | 34422.08  |       |        |
|   |                                        | 12053.91  | 15.8963 | 17211.04  | 8.65  | 83.83  |
| 8 | <b>Net Capital Turnover Ratio</b>      |           |         |           |       |        |
|   | Net Sales                              |           |         |           |       |        |
|   | Net Working Capital                    |           |         |           |       |        |
|   | Net Sales                              | 240233.85 |         | 195382.48 |       |        |
|   | Net Working Capital                    |           |         |           |       |        |
|   | Current Assets                         | 84751.76  |         | 78319.12  |       |        |
|   | Less: Current Liabilities              | 45224.02  |         | 42671.50  |       |        |
|   |                                        | 39527.74  | 6.0776  | 35647.62  | 5.48  | 10.89  |
| 9 | <b>Net Profit Ratio</b>                |           |         |           |       |        |
|   | Net Profit                             |           |         |           |       |        |
|   | Sales                                  |           |         |           |       |        |



|    |                                      |           |         |           |       |        |
|----|--------------------------------------|-----------|---------|-----------|-------|--------|
|    | Net Profit (After Taxes)             | 5625.34   |         | 828.80    |       |        |
|    | Sales                                | 240233.85 | 0.02342 | 195382.48 | 0.004 | 452.01 |
| 10 | <b>Return on Capital Employed</b>    |           |         |           |       |        |
|    | Earning before Interest and Taxes    |           |         |           |       |        |
|    | Capital Employed                     |           |         |           |       |        |
|    | Earning before Interest and Taxes    |           |         |           |       |        |
|    | Net Profit                           | 8584.95   |         | 1348.74   |       |        |
|    | Add: Interest                        | 3600.96   |         | 4196.34   |       |        |
|    | Total                                | 12185.90  |         | 5545.08   |       |        |
|    | Capital Employed                     |           |         |           |       |        |
|    | (Total Assets - Current Liabilities) |           |         |           |       |        |
|    | Total Assets                         | 92064.61  |         | 86903.44  |       |        |
|    | Less: Current Liabilities            | 45224.02  |         | 42671.50  |       |        |
|    |                                      | 46840.58  | 0.26016 | 44231.94  | 0.125 | 107.52 |
| 11 | <b>Return on Investment</b>          |           |         |           |       |        |
|    | Profit                               | -         |         | -         |       |        |
|    | Investment                           | -         | -       | -         | -     |        |

**Reason for Variance**

- 1 There is no significant change in the key financial ratio (Less than 25%)
- 2 Debts increased as compare to previous year, therefore ratio increased.
- 3 Earning for Debt Service increased as compare to previous year, therefore ratio increased.
- 4 Net Profit After Tax increased as compare to previous year, therefore ratio increased.
- 5 There is no significant change in the key financial ratio (Less than 25%)
- 6 There is no significant change in the key financial ratio (Less than 25%)
- 7 Net Credit Purchase increased as compare to previous year, therefore ratio increased.
- 8 There is no significant change in the key financial ratio (Less than 25%)
- 9 Net Profit After Tax increased as compare to previous year, therefore ratio increased.
- 10 Earning increased as compare to previous year, therefore ratio increased.
- 11 There is no earning from Investment



**Notes on Financial Statement for the year ended 31st March, 2025**

(In Rs.,000)

|  | 2025 | 2024 |
|--|------|------|
|--|------|------|

The previous year figures have been regrouped / reclassified, wherever necessary to confirm to the current year presentation

**2. SHARE CAPITAL****Authorized Share Capital :**

|                                         |          |          |
|-----------------------------------------|----------|----------|
| 10,00,000 Equity shares of Rs.10/- each | 10000.00 | 10000.00 |
| (Previous Year 10,00,000 Equity Shares) |          |          |

**Issued, Subscribed and Paid up :**

|                                                        |         |         |
|--------------------------------------------------------|---------|---------|
| 9,54,000 Equity Shares of Rs.10/- each fully paid up   | 9540.00 | 9540.00 |
| (Previous Year 9,54,000 Equity Shares of Rs.10/- each) |         |         |

|              |                |                |
|--------------|----------------|----------------|
| <b>Total</b> | <b>9540.00</b> | <b>9540.00</b> |
|--------------|----------------|----------------|

**The details of Shareholders holding more than 5% Shares:**

| Name of the Shareholders | 2025       |        | 2024         |        |
|--------------------------|------------|--------|--------------|--------|
|                          | No. of Sha | % held | No. of Share | % held |
| Sanjay Manocha           | 286200     | 30.00  | 506250       | 53.07  |
| Yogesh Sachdeva          | 286200     | 30.00  | 447750       | 46.93  |
| Sukesh Arora             | 286200     | 30.00  | -            | -      |
| Kartik Palta             | 95400      | 10.00  | -            | -      |

**Shares held by the Promoters at the end of the year as below:**

| Sr.No        | Promoters Name  | No of Shares  | % of total Shares | % change during the year |
|--------------|-----------------|---------------|-------------------|--------------------------|
| 01.          | Sanjay Manocha  | 286200        | 30.00             | -23.07                   |
| 02.          | Yogesh Sachdeva | 286200        | 30.00             | -16.93                   |
| 02.          | Sukesh Arora    | 286200        | 30.00             | 30.00                    |
| 02.          | Kartik Palta    | 95400         | 10.00             | 10.00                    |
| <b>Total</b> |                 | <b>954000</b> | <b>100.00</b>     | <b>-</b>                 |

**The Reconciliation of the numbers of shares outstanding is set out below:**

|                                            | 2025   | 2024   |
|--------------------------------------------|--------|--------|
| Equity Shares at the beginning of the year | 954000 | 954000 |
| Add: Bonus Share Issued during the year    | -      | -      |
| Equity Shares at the end of the year       | 954000 | 954000 |

**Terms/rights attached to Equity Shares**

The company has only one class of equity shares having a par value of Rs.10 per share. All these shares have same rights and preferences with respect to payment of dividend, repayment of capital and voting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

**3. RESERVES AND SURPLUS****Profit & Loss Account**

|                            | 2025            | 2024            |
|----------------------------|-----------------|-----------------|
| As per Last Balance Sheet  | 26404.97        | 25573.16        |
| Add: Profit for the year   | 5625.34         | 828.80          |
| Add: Income Tax Adjustment | -               | 3.01            |
| <b>Total</b>               | <b>32030.31</b> | <b>26404.97</b> |



**Notes on Financial Statement for the year ended 31st March, 2025**

(In Rs.,000)

|                                         | 2025           | 2024           |
|-----------------------------------------|----------------|----------------|
| <b>4. LONG TERM BORROWINGS</b>          |                |                |
| Term Loan:-Rupee Loan from Bank-Secured | 3552.59        | 6563.71        |
| Loan and Advances                       | -              | 1573.26        |
| <b>Total</b>                            | <b>3552.59</b> | <b>8136.97</b> |

**Security**

(i) Term Loans from Banks is secured by way of Specific charge on asset under Hypothecation relating to automobile financing.

(ii) Term Loans (other than automobile) from Banks is secured by way of personal guarantee of Directors.

**5. OTHER NON CURRENT LIABILITIES**

|                   |          |               |
|-------------------|----------|---------------|
| Security Deposits | -        | 150.00        |
| <b>Total</b>      | <b>-</b> | <b>150.00</b> |

**6. NON CURRENT PROVISIONS**

|                                |                |          |
|--------------------------------|----------------|----------|
| Provision for Gratuity         | 1404.48        | -        |
| Provision for Leave Encashment | 313.20         | -        |
| <b>Total</b>                   | <b>1717.68</b> | <b>-</b> |

**7.SHORT TERM BORROWINGS**

|                                         |                 |                 |
|-----------------------------------------|-----------------|-----------------|
| Working Capital Loans from Bank-Secured | 21423.21        | 19797.26        |
| Term Loan:-Rupee Loan from Bank-Secured | 3647.42         | 4964.53         |
| Loan and Advances-Related Parties       | 2024.56         | 1400.00         |
| <b>Total</b>                            | <b>27095.18</b> | <b>26161.79</b> |

**Security**

(i) Working Capital Loans are secured by hypothecation of present and future stock, book debts, material in transit , etc.

(ii) Term Loans from Banks is secured by way of Specific charge on asset under Hypothecation relating to automobile financing.

(iii) Term Loans (other than automobile) from Banks is secured by way of personal guarantee of Directors.

(iv) Current maturities of Long Term Borrowings shall be disclosed separately

**8. TRADE PAYABLES**

|                                        |                 |                 |
|----------------------------------------|-----------------|-----------------|
| (i)Micro, Small and Medium Enterprises |                 |                 |
| -Less Than 1 Year                      | 3125.11         | 14078.32        |
| - 1-2 Years                            | -               | -               |
| - 2-3 Years                            | -               | -               |
| - More than 3 Years                    | -               | -               |
| (ii)Others                             | -               | -               |
| -Less Than 1 Year                      | 6904.39         | -               |
| (iii) Disputed Dues-MSME               | -               | -               |
| (iii) Disputed Dues-Others             | -               | -               |
| <b>Total</b>                           | <b>10029.50</b> | <b>14078.32</b> |



**9.OTHER CURRENT LIABILITIES**

|                        |                |                |
|------------------------|----------------|----------------|
| Statutory Dues         | 842.09         | 446.69         |
| Salary Payable         | 1233.36        | 982.58         |
| Other Payables         | 1870.44        | 403.09         |
| Advance from Customers | 1346.85        | 599.04         |
| <b>Total</b>           | <b>5292.74</b> | <b>2431.40</b> |

**10.CURRENT PROVISIONS**

|                                |                |          |
|--------------------------------|----------------|----------|
| Provision for Income Tax       | 2750.00        | -        |
| Provision for Gratuity         | 34.38          | -        |
| Provision for Leave Encashment | 22.22          | -        |
| <b>Total</b>                   | <b>2806.60</b> | <b>-</b> |



Notes on Financial Statement for the year ended 31st March, 2025

11. PROPERTY, PLANT AND EQUIPMENT

(In Rs.,000)

| Particulars             | Original Cost     |                |                | Depreciation      |                   |                 | Net Book Value    |                   |                   |
|-------------------------|-------------------|----------------|----------------|-------------------|-------------------|-----------------|-------------------|-------------------|-------------------|
|                         | As at<br>01.04.24 | Addition       | Ded.           | As at<br>31.03.25 | As at<br>01.04.24 | For the<br>Year | As at<br>31.03.25 | As at<br>31.03.25 | As at<br>31.03.24 |
| <b>TANGIBLE ASSETS:</b> |                   |                |                |                   |                   |                 |                   |                   |                   |
| <b>OWN ASSETS:</b>      |                   |                |                |                   |                   |                 |                   |                   |                   |
| Office Equipment        | 1053.11           | 174.82         | -              | 1227.93           | 914.33            | 61.53           | -                 | 975.87            | 252.06            |
| Furniture & Fixture     | 344.87            | -              | -              | 344.87            | 314.68            | 3.17            | -                 | 317.85            | 27.02             |
| Computer                | 910.12            | 72.59          | -              | 982.71            | 856.93            | 30.79           | -                 | 887.71            | 95.00             |
| Vehicle                 | 7588.76           | -              | 3578.20        | 4010.56           | 3670.36           | 1169.24         | 3345.00           | 1494.59           | 2515.97           |
| Commercial Vehicle      | 423.44            | 1016.65        | -              | 1440.09           | 396.02            | 336.91          | -                 | 732.93            | 707.16            |
| Machine                 | 5331.72           | -              | -              | 5331.72           | 2642.26           | 486.79          | -                 | 3129.06           | 2202.66           |
| <b>Sub Total</b>        | <b>15652.01</b>   | <b>1264.06</b> | <b>3578.20</b> | <b>13337.87</b>   | <b>8794.58</b>    | <b>2088.42</b>  | <b>3345.00</b>    | <b>7538.00</b>    | <b>5799.87</b>    |
| <b>Previous Year</b>    | <b>11806.53</b>   | <b>5809.06</b> | <b>1963.57</b> | <b>15652.01</b>   | <b>9955.90</b>    | <b>722.60</b>   | <b>1883.92</b>    | <b>8794.58</b>    | <b>6857.43</b>    |



**Notes on Financial Statement for the year ended 31st March, 2025**

(In Rs.,000)

|                                | 2025          | 2024          |
|--------------------------------|---------------|---------------|
| <b>12. DEFERRED TAX ASSETS</b> |               |               |
| Deferred Tax Assets            | 223.07        | 432.68        |
| <b>Total</b>                   | <b>223.07</b> | <b>432.68</b> |

**13. OTHER LONG TERM ASSETS**

[Unsecured-Considered Good (Unless Otherwise Stated)]

|                  |                |                |
|------------------|----------------|----------------|
| Security Deposit | 1289.90        | 1294.21        |
| <b>Total</b>     | <b>1289.90</b> | <b>1294.21</b> |

**14. INVENTORIES**

|                |                 |                 |
|----------------|-----------------|-----------------|
| Stock-in-Trade | 18168.14        | 13027.03        |
| <b>Total</b>   | <b>18168.14</b> | <b>13027.03</b> |

**15. TRADE RECEIVABLE**

(i) Undisputed Trade Receivable-Considered Good

|                     |          |          |
|---------------------|----------|----------|
| -Less Than 6 Months | 56927.78 | 39509.20 |
| -6 Months-1Year     | 1781.01  | 418.10   |
| -1 -2 Years         | -        | 5965.38  |
| -2 -3 Years         | 226.95   | 5353.51  |
| -More than 3 Years  | 983.51   | 713.63   |

(ii) Undisputed Trade Receivable-Considered Doubtful

|  |   |   |
|--|---|---|
|  | - | - |
|--|---|---|

(iii) Disputed Trade Receivable-Considered Good

|  |   |   |
|--|---|---|
|  | - | - |
|--|---|---|

(v) Disputed Trade Receivable-Considered Doubtful

|              |                 |                 |
|--------------|-----------------|-----------------|
|              | -               | 3256.13         |
| <b>Total</b> | <b>59919.25</b> | <b>55215.94</b> |

**16. CASH AND CASH EQUIVALENTS**

|                           |                |                |
|---------------------------|----------------|----------------|
| Cash on Hand              | 510.31         | 351.37         |
| Balance with Bank         | -              | -              |
| Fixed Deposits with banks | 4799.56        | 7120.96        |
| <b>Total</b>              | <b>5309.87</b> | <b>7472.33</b> |

**17. SHORT TERM LOANS AND ADVANCES**

[Unsecured-Considered Good (Unless Otherwise Stated)]

|                      |               |                |
|----------------------|---------------|----------------|
| Capital Advance      | -             | -              |
| Prepaid Expenses     | 180.89        | 235.41         |
| Advance to Suppliers | 332.74        | 2111.68        |
| Employee Advance     | -10.16        | 14.18          |
| Others               | -             | 49.31          |
| <b>Total</b>         | <b>503.47</b> | <b>2410.57</b> |

**18. OTHER ASSETS**

Unsecured-Considered Good (Unless Otherwise Stated)

|                                |               |               |
|--------------------------------|---------------|---------------|
| GST Input Credit               | 440.00        | 10.33         |
| Advance Tax & TDS (Net of Tax) | 406.14        | 4.88          |
| GST Refund                     | 4.88          | 178.04        |
| <b>Total</b>                   | <b>851.03</b> | <b>193.25</b> |



**Notes on Financial Statement for the year ended 31st March, 2025**

(In Rs.,000)

|                                                   | <b>2025</b>      | <b>2024</b>      |
|---------------------------------------------------|------------------|------------------|
| <b>19.REVENUE FROM OPERATIONS</b>                 |                  |                  |
| Sale of Products                                  | 244703.20        | 195382.48        |
| Less: Inter unit Transfer                         | 4469.35          | -                |
| <b>Total</b>                                      | <b>240233.85</b> | <b>195382.48</b> |
| <b>20.OTHER INCOME</b>                            |                  |                  |
| Interest FDR                                      | 266.38           | 242.75           |
| Interest -I Tax                                   | -                | 9.99             |
| Custom Duty Drawback                              | -                | 20.77            |
| Profit on Sale of Fixed Assets                    | 766.81           | 20.35            |
| <b>Total</b>                                      | <b>1033.19</b>   | <b>293.86</b>    |
| <b>21.PURCHASE OF STOCK IN TRADE</b>              |                  |                  |
| Purchase of stock-in-trade                        | 196081.40        | 148831.25        |
| Less: Inter unit Transfer                         | 4469.35          | -                |
| <b>Total</b>                                      | <b>191612.05</b> | <b>148831.25</b> |
| <b>22.CHANGE IN INVENTORIES OF STOCK-IN-TRADE</b> |                  |                  |
| Stock-in-Trade (at close)                         | 18168.14         | 13027.03         |
| Stock-in-Trade (at commencement)                  | 13027.03         | 17517.68         |
| <b>Total</b>                                      | <b>-5141.11</b>  | <b>4490.65</b>   |
| <b>23.EMPLOYEE BENEFIT EXPENSES</b>               |                  |                  |
| Salaries and Wages                                | 17718.03         | 17725.03         |
| Contribution to Provident Fund and other funds    | 559.58           | 638.95           |
| Provision for Gratuity                            | 1438.86          | -                |
| Provision for Leave Encashment                    | 335.42           | -                |
| Staff Welfare Expenses                            | 368,317          | 186.78           |
| <b>Total</b>                                      | <b>20420.21</b>  | <b>18550.76</b>  |
| <b>24. FINANCE COST</b>                           |                  |                  |
| Interest Expenses                                 | 3600.96          | 4196.34          |
| <b>Total</b>                                      | <b>3600.96</b>   | <b>4196.34</b>   |
| <b>25.DEPRECIATION AND AMORTISATION EXPENSES</b>  |                  |                  |
| Depreciation and Amortisation                     | 2088.42          | 722.60           |
| <b>Total</b>                                      | <b>2088.42</b>   | <b>722.60</b>    |



**Notes on Financial Statement for the year ended 31st March, 2025**

|                                 | <b>2025</b>     | <b>2024</b>     |
|---------------------------------|-----------------|-----------------|
| <b>26.OTHER EXPENSE</b>         |                 |                 |
| Custom Duty                     | 79.66           | 68.65           |
| Packing Expenses                | 19.85           | 141.59          |
| Freight                         | 5234.78         | 3822.02         |
| Rent                            | 1672.00         | 1967.68         |
| Power & Fuel                    | 337.93          | 158.01          |
| Communication Cost              | 67.25           | 107.75          |
| Traveling & Conveyance Expenses | 2790.43         | 2723.55         |
| Business Promotions Expenses    | 454.65          | 369.63          |
| Commission Expenses             | 2460.90         | 4100.27         |
| Office Expenses                 | 821.45          | 639.81          |
| Insurance Expenses              | 342.45          | 187.81          |
| Repair & Maintenance Expenses   | 670.45          | 544.75          |
| Printing & Stationery Expenses  | 218.59          | 121.69          |
| Professional Fees               | 991.76          | 917.60          |
| Festival Expenses               | 668.73          | 444.52          |
| Charity & Donations             | 50.00           | -               |
| Bad Debts                       | 1927.81         | -               |
| Discount & Rebates              | 966.18          | 943.57          |
| GST Expenses                    | 324.89          | 197.50          |
| Legal Fee                       | -               | 79.60           |
| Other Overheads                 | 1.79            | -               |
| <b>Total</b>                    | <b>20101.56</b> | <b>17536.00</b> |



**Notes on Financial Statement for the year ended 31st March, 2025**

|                                             | DLI                 | WZ                   | In ₹<br>2025         |
|---------------------------------------------|---------------------|----------------------|----------------------|
| <b>2.SHARE CAPITAL</b>                      |                     |                      |                      |
| Share Capital                               | 9,540,000.00        | -                    | 9,540,000.00         |
| <b>Total</b>                                | <b>9,540,000.00</b> | <b>-</b>             | <b>9,540,000.00</b>  |
| <b>3.RESERVE &amp; SURPLUS</b>              |                     |                      |                      |
| Profit & Loss Account                       | 1,958,629.96        | 30,071,678.60        | 32,030,308.56        |
| <b>Total</b>                                | <b>1,958,630.00</b> | <b>30,071,678.60</b> | <b>32,030,308.56</b> |
| <b>4.LONG TERM BORROWINGS</b>               |                     |                      |                      |
| Term Loan:-Rupee Loan from Bank-Secured     | -                   | 3,552,591.00         | 3,552,591.00         |
| Loan and Advances from related parties      | -                   | -                    | -                    |
| Loan and Advances from others               | -                   | -                    | -                    |
| <b>Total</b>                                | <b>-</b>            | <b>3,552,591.00</b>  | <b>3,552,591.00</b>  |
| <b>5.OTHER NON CURRENT LIABILITIES</b>      |                     |                      |                      |
| Security Deposits                           | -                   | -                    | -                    |
| <b>Total</b>                                | <b>-</b>            | <b>-</b>             | <b>-</b>             |
| <b>6.NON CURRENT PROVISIONS</b>             |                     |                      |                      |
| Provisions- Gratuity                        | -                   | 1,404,480.00         | 1,404,480.00         |
| Provisions- LeaveEncashment                 | -                   | 313,203.00           | 313,203.00           |
| <b>Total</b>                                | <b>-</b>            | <b>1,717,683.00</b>  | <b>1,717,683.00</b>  |
| <b>7.SHORT TERM BORROWINGS</b>              |                     |                      |                      |
| Working Capital Loans from Bank-Secured     | -                   | 21,423,205.29        | 21,423,205.29        |
| Term Loan:-Rupee Loan from Bank-Secured     | -                   | 3,647,416.70         | 3,647,416.70         |
| Loan and Advances from related parties      | -                   | 2,024,562.00         | 2,024,562.00         |
| <b>Total</b>                                | <b>-</b>            | <b>27,095,183.99</b> | <b>27,095,183.99</b> |
| <b>8. TRADE PAYABLES</b>                    |                     |                      |                      |
| (i)Micro, Small and Medium Enterprises      |                     |                      |                      |
| -Less Than 1 Year                           | -                   | 3,125,112.72         | 3,125,112.72         |
| -1-2 Years                                  | -                   | -                    | -                    |
| -2-3 Years                                  | -                   | -                    | -                    |
| - More than 3 Years                         | -                   | -                    | -                    |
| (ii)Others                                  |                     |                      |                      |
| -Less Than 1 Year                           | -                   | 6,904,389.34         | 6,904,389.34         |
| (iii) Disputed Dues-MSME                    | -                   | -                    | -                    |
| (iii) Disputed Dues-Others                  | -                   | -                    | -                    |
| <b>Total</b>                                | <b>-</b>            | <b>10,029,502.06</b> | <b>10,029,502.00</b> |
| <b>9.OTHER CURRENT LIABILITIES</b>          |                     |                      |                      |
| Statutory Dues                              | -                   | 842,090.00           | 842,090.00           |
| Salary Payable                              | -                   | 1,233,361.00         | 1,233,361.00         |
| Advance from Customers                      | -                   | 1,870,441.25         | 1,870,441.25         |
| Other Payables                              | 2,122.00            | 1,344,727.93         | 1,346,849.93         |
| <b>Total</b>                                | <b>2,122.00</b>     | <b>5,290,620.18</b>  | <b>5,292,742.00</b>  |
| <b>10.SHORT TERM PROVISIONS</b>             |                     |                      |                      |
| Provisions for Income Tax(Net of Adv Taxes) | -                   | 2,750,000.00         | 2,750,000.00         |
| Provisions- Gratuity                        | -                   | 34,380.00            | 34,380.00            |
| Provisions- LeaveEncashment                 | -                   | 22,215.00            | 22,215.00            |
| <b>Total</b>                                | <b>-</b>            | <b>2,806,595.00</b>  | <b>2,806,595.00</b>  |
| Branch Balance                              | -2,672,082.39       | 2,672,082.39         | -                    |
| <b>TOTAL</b>                                | <b>8,828,669.61</b> | <b>83,235,936.22</b> | <b>92,064,605.55</b> |



**O.FIXED ASSETS**

|               |                     |                     |                     |
|---------------|---------------------|---------------------|---------------------|
| As on 31.3.25 | 1,597,813.86        | 4,202,058.20        | 5,799,872.06        |
| <b>Total</b>  | <b>1,597,814.00</b> | <b>4,202,058.20</b> | <b>5,799,872.20</b> |

**10. DEFERRED TAX ASSETS (Net)****Deferred Tax Assets**

|                         |                   |          |                   |
|-------------------------|-------------------|----------|-------------------|
| Related to Fixed Assets | 223,070.00        | -        | 223,070.00        |
| <b>Total</b>            | <b>223,070.00</b> | <b>-</b> | <b>223,070.00</b> |

**12.Other Non Current Assets**

[Unsecured-Considered Good (Unless Otherwise Stated)]

|                  |                   |                   |                     |
|------------------|-------------------|-------------------|---------------------|
| Security Deposit | 949,032.00        | 340,871.00        | 1,289,903.00        |
| <b>Total</b>     | <b>949,032.00</b> | <b>340,871.00</b> | <b>1,289,903.00</b> |

**13.INVENTORIES**

|                |          |                      |                      |
|----------------|----------|----------------------|----------------------|
| Stock-in-Trade | -        | 18,168,137.60        | 18,168,137.60        |
| <b>Total</b>   | <b>-</b> | <b>18,168,137.60</b> | <b>18,168,138.00</b> |

**14. TRADE RECEIVABLE**

(i)Undisputed Trade Receivable-Considered Good

|                     |            |               |               |
|---------------------|------------|---------------|---------------|
| -Less Than 6 Months | -          | 56,927,781.40 | 56,927,781.40 |
| -6 Months-1Year     | -          | 1,781,008.67  | 1,781,008.67  |
| -1 -2 Years         | -          | -             | -             |
| -2 -3 Years         | 226,950.14 | -             | 226,950.14    |
| -More than 3 Years  | 983,507.19 | -             | 983,507.19    |

(ii)Undisputed Trade Receivable-Considered Doubtful

(iii)Disputed Trade Receivable-Considered Good

(v)Disputed Trade Receivable-Considered Doubtful

|              |                     |                      |                      |
|--------------|---------------------|----------------------|----------------------|
| <b>Total</b> | <b>1,210,457.33</b> | <b>58,708,790.07</b> | <b>59,919,247.40</b> |
|--------------|---------------------|----------------------|----------------------|

**15. CASH AND CASH EQUIVALENTS**

|                           |                     |                   |                     |
|---------------------------|---------------------|-------------------|---------------------|
| Cash on Hand              | 1,968.94            | 508,344.07        | 510,313.01          |
| Bank Balance With Banks   | -                   | -                 | -                   |
| Fixed Deposits with banks | 4,799,561.48        | -                 | 4,799,561.48        |
| <b>Total</b>              | <b>4,801,530.42</b> | <b>508,344.07</b> | <b>5,309,874.49</b> |

**16.SHORT TERM LOANS AND ADVANCES**

[Unsecured-Considered Good (Unless Otherwise Stated)]

|                      |          |                   |                   |
|----------------------|----------|-------------------|-------------------|
| Capital Advance      | -        | -                 | -                 |
| Prepaid Expenses     | -        | 180,890.00        | 180,890.00        |
| Advance to Suppliers | -        | 332,738.63        | 332,738.63        |
| Employee Advance     | -        | 10,157.26         | 10,157.26         |
| Others               | -        | -                 | -                 |
| <b>Total</b>         | <b>-</b> | <b>503,471.37</b> | <b>503,471.37</b> |

**17.OTHER ASSETS**

Unsecured-Considered Good (Unless Otherwise Stated)]

|                   |                  |                   |                   |
|-------------------|------------------|-------------------|-------------------|
| GST Input Credit  | 3,833.76         | 436,169.12        | 440,002.88        |
| Advance Tax & TDS | 38,050.00        | 368,093.99        | 406,143.99        |
| GST Refund        | 4,882.00         | -                 | 4,882.00          |
| <b>Total</b>      | <b>46,766.00</b> | <b>804,263.00</b> | <b>851,029.00</b> |

Branch Balance

|                     |                      |                      |
|---------------------|----------------------|----------------------|
| <b>8,828,670.36</b> | <b>83,235,935.31</b> | <b>92,064,605.46</b> |
|---------------------|----------------------|----------------------|

|       |      |      |
|-------|------|------|
| -0.75 | 0.91 | 0.09 |
|-------|------|------|



**Notes on Financial Statement for the year ended 31st March, 2025**

In ₹

|                                    | DLI              | Wazirpur           | TOTAL              |
|------------------------------------|------------------|--------------------|--------------------|
| <b>18. REVENUE FROM OPERATIONS</b> |                  |                    |                    |
| Sale of Products                   | 7,422,999        | 237,280,202        | 244,703,201        |
| <b>Total</b>                       | <b>7,422,999</b> | <b>237,280,202</b> | <b>244,703,201</b> |

**19. OTHER INCOME**

|                                |                  |          |                  |
|--------------------------------|------------------|----------|------------------|
| Profit on Sale of Fixed Assets | 766,806          | -        | 766,806          |
| Interest FDR                   | 266,382          | -        | 266,382          |
| <b>Total</b>                   | <b>1,033,188</b> | <b>-</b> | <b>1,033,188</b> |

**20. PURCHASE OF STOCK IN TRADE**

|                            |                  |                    |                    |
|----------------------------|------------------|--------------------|--------------------|
| Purchase of stock-in-trade | 4,669,350        | 191,412,053        | 196,081,403        |
| <b>Total</b>               | <b>4,669,350</b> | <b>191,412,053</b> | <b>196,081,403</b> |

**21. CHANGE IN INVENTORIES OF STOCK-IN-TRADE**

|                                  |          |                   |                   |
|----------------------------------|----------|-------------------|-------------------|
| Stock-in-Trade (at close)        | -        | 18,168,138        | 18,168,138        |
| Stock-in-Trade (at commencement) | -        | 13,027,033        | 13,027,033        |
| <b>Total</b>                     | <b>-</b> | <b>-5,141,105</b> | <b>-5,141,105</b> |

**22. EMPLOYEE BENEFIT EXPENSES**

|                                            |          |                   |                   |
|--------------------------------------------|----------|-------------------|-------------------|
| Salaries and Wages                         | -        | 17,718,030        | 17,718,030        |
| Contribution to Provident Fund and other f | -        | 559,582           | 559,582           |
| Provision for Gratuity                     | -        | 1,438,860         |                   |
| Provision for Leave Encashment             | -        | 335,418           |                   |
| Staff Welfare Expenses                     | -        | 368,317           | 368,317           |
| <b>Total</b>                               | <b>-</b> | <b>20,420,207</b> | <b>18,645,929</b> |

**23. FINANCE COST**

|                   |          |                  |                  |
|-------------------|----------|------------------|------------------|
| Interest Expenses | -        | 3,600,955        | 3,600,955        |
| <b>Total</b>      | <b>-</b> | <b>3,600,955</b> | <b>3,600,955</b> |

**24. DEPRECIATION AND AMORTISATION EXPENSES**

|                               |                |                  |                  |
|-------------------------------|----------------|------------------|------------------|
| Depreciation and Amortisation | 551,439        | 1,536,984        | 2,088,423        |
| <b>Total</b>                  | <b>551,439</b> | <b>1,536,984</b> | <b>2,088,423</b> |



**Notes on Financial Statement for the year ended 31st March, 2025**

|                                 | <b>DLI</b>       | <b>Wazirpur</b>   | <b>Total</b>      |
|---------------------------------|------------------|-------------------|-------------------|
| <b>25.OTHER EXPENSE</b>         |                  |                   |                   |
| Custom Duty                     | -                | 79,661            | 79,661            |
| Clearing & Forwarding           | -                | -                 | -                 |
| Packing Expenses                | -                | 19,852            | 19,852            |
| Freight                         | 55,084           | 5,179,697         | 5,234,781         |
| Rent                            | 513,000          | 1,159,000         | 1,672,000         |
| Power & Fuel                    |                  | 337,929           | 337,929           |
| Communication Cost              | 37,274           | 29,972            | 67,246            |
| Traveling & Conveyance Expenses | 9,874            | 2,780,558         | 2,790,432         |
| Business Promotions Expenses    | 9,989            | 444,663           | 454,652           |
| Commission Expenses             |                  | 2,460,899         | 2,460,899         |
| Office Expenses                 | 3,100            | 818,349           | 821,449           |
| Insurance Expenses              | 117,348          | 225,102           | 342,450           |
| Repair & Maintenance Expenses   | 63,297           | 607,154           | 670,451           |
| Printing & Stationery Expenses  |                  | 218,590           | 218,590           |
| Professional Fees               | 66,000           | 925,755           | 991,755           |
| Festival Expenses               |                  | 668,732           | 668,732           |
| Donations                       |                  | 50,000            | 50,000            |
| Bad Debts                       |                  | 1,927,813         | 1,927,813         |
| Discount & Rebates              |                  | 966,181           | 966,181           |
| GST Expenses                    | 191,800          | 133,093           | 324,893           |
| Legal fee                       |                  | -                 | -                 |
| Other Overheads                 | 392              | 1,400             | 1,791             |
| <b>Total</b>                    | <b>1,067,158</b> | <b>19,034,399</b> | <b>20,101,557</b> |

|                          |                  |                  |                  |
|--------------------------|------------------|------------------|------------------|
|                          | 2,168,240        | 6,416,708        | 8,584,948        |
| Less: Deferred Tax       | 209,610          | -                | 209,610          |
| Provision for Income Tax | -                | 2,750,000        | 2,750,000        |
|                          | <b>1,958,630</b> | <b>3,666,708</b> | <b>5,625,338</b> |

OKEY

OKEY

OKEY




## NOTICE

Notice is hereby given that the 18th (Eighteenth) Annual General Meeting of the Members of M. S. Medicals Private Limited will be held on Tuesday the 30th day of September 2025 at 10:30 A.M. at the registered office of the Company situated at LG - 2A Mohan Bazar Central Market, Ashok Vihar, Phase 1 Delhi - 110052 to transact the following business:

### ORDINARY BUSINESS:

01.To receive, consider and adopt the Audited Financial Statement of the Company for the financial year ended 31st March, 2025 and the reports of the Board of Directors and Auditors thereon.

For and on the behalf of Board of Directors  
M. S. Medicals Private Limited

  
YOGESH SACHDEVA  
(Director)  
DIN: 00077095

  
SANJAY MANOCHA  
(Director)  
DIN: 00076997

Place: New Delhi

Date: 16.07.2025

### NOTES:

1. A member entitled to attend and vote is entitled to appoint a proxy or proxies to attend and, on a poll, to vote on his behalf and the proxy need not be a member. A person can act as a proxy on behalf of members not exceeding 50 and holding in the aggregate not more than 10% of the total Share Capital of the Company carrying voting rights. In case a proxy is proposed to be appointed by a member holding more than 10% of the total Share Capital of the Company carrying voting Rights, than such proxy shall not act as a proxy for any other person member.
2. The Notice is being sent to all the Members along with the copy of the Annual Report including the Financial Statements, Boards Report etc.
3. All documents referred to in the accompanying Notice are open for inspection at the Registered Office of the Company on all working days, except Sundays between 10.00 A.M. and 2.00 P.M up to the date of the Annual General Meeting.
4. Corporate Members intending to send their authorized representatives are requested to send a duly certified copy of the Board Resolution authorizing their representatives to attend and vote at the Annual General Meeting.

## M S Medicals Pvt. Ltd.

Corporate Office : N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

Tel.: (O) 011-4569 7024 | 4506 7231

Warehouse : C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) Tel.: (O) 011-40574967

E-mail : [info@msmedicals.in](mailto:info@msmedicals.in) / [info1@msmedicals.in](mailto:info1@msmedicals.in) / [yogesh@msmedicals.in](mailto:yogesh@msmedicals.in) / [accounts@msmedicals.in](mailto:accounts@msmedicals.in) | Website : [www.msmedicals.in](http://www.msmedicals.in)

## DIRECTORS REPORT FOR THE FINANCIAL YEAR 2024-2025

To,  
The Members,  
M. S. Medicals Private Limited

The Board of Directors are pleased to present the 18<sup>th</sup> (Eighteenth) Annual Report and the Company's Audited Financial Statements for the financial year ended March 31, 2025.

### 1. FINANCIAL RESULTS

The Company's financial performance for the year ended March 31, 2025 is summarized below:

|                     | Amount in Rs.            |                          |
|---------------------|--------------------------|--------------------------|
|                     | Year Ended<br>31.03.2025 | Year Ended<br>31.03.2024 |
| Net Sales/ Receipts | 24,12,67,039             | 19,56,76,339             |
| Total Expenditure   | 23,26,82,090             | 19,43,27,595             |
| Profit before taxes | 85,84,949                | 13,48,744                |
| Less: Current Tax   | 27,50,000                | 1,84,180                 |
| Less: Deferred Tax  | 2,09,610                 | 3,35,760                 |
| Profit after taxes  | 56,25,339                | 8,28,804                 |
| Earnings per share  | 5.90                     | 0.87                     |

### 2. FINANCIAL HIGHLIGHTS

The Highlight of the Company's performance for the year ended 31<sup>st</sup> March 2025, are as under:

The Profit after Tax is Rs. 5625339 as compared to Rs. 828804 in the previous year.

### 3. DIVIDEND

The Board of Directors of your Company have not recommended any dividend for the Financial Year ended 31<sup>st</sup> March 2025.

### 4. CHANGE IN THE NATURE OF BUSINESS AND MATERIAL CHANGES BETWEEN THE DATE OF THE BOARD REPORT AND END OF FINANCIAL YEAR

There has been no change in the nature of business of the Company. There have been no material changes and commitments affecting the financial position of the Company between the end of the financial year and the date of this report.

**M S Medicals Pvt. Ltd.**

Corporate Office : N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

Tel.: (O) 011-4569 7024 | 4506 7231

Warehouse : C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) Tel.: (O) 011-40574967

E-mail : [info@msmedicals.in](mailto:info@msmedicals.in) / [info1@msmedicals.in](mailto:info1@msmedicals.in) / [yogesh@msmedicals.in](mailto:yogesh@msmedicals.in) / [accounts@msmedicals.in](mailto:accounts@msmedicals.in) | Website : [www.msmedicals.in](http://www.msmedicals.in)

**5 SUBSIDIARY & ASSOCIATE COMPANY**

As on March 31, 2025, the Company does not have any subsidiary/joint venture/associate companies.

**6 DIRECTORS RESPONSIBILITY STATEMENT**

Pursuant to Section 134(5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors confirm that:

- i) in the preparation of the annual accounts of the year ended March 31, 2025, the applicable accounting standards have been followed along with proper explanations relating to any material departures, if any;
- ii) they have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2025 and of the profit of the Company for the year ended on that date;
- iii) they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- iv) that the Annual Accounts are prepared on a going concern basis;
- v) that they have laid down proper internal financial controls to be followed by the company and that internal financial controls are adequate and are operating effectively; and
- vi) they have devised proper systems to ensure compliance with the provisions of all applicable laws and these systems are adequate and operating effectively.

**7. RELATED PARTY TRANSACTIONS**

Related party transactions were entered into by the Company during the financial year. Related party transactions entered by the Company during the financial year were in the ordinary course of business and on arm's length basis which did not conflict with the interest of the Company.

## MS Medicals Pvt. Ltd.

**Corporate Office :** N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

**Tel.:** (O) 011-4569 7024 | 4506 7231

**Warehouse :** C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) **Tel.:** (O) 011-40574967

**E-mail :** [info@msmedicals.in](mailto:info@msmedicals.in) / [info1@msmedicals.in](mailto:info1@msmedicals.in) / [yogesh@msmedicals.in](mailto:yogesh@msmedicals.in) / [accounts@msmedicals.in](mailto:accounts@msmedicals.in) | **Website :** [www.msmedicals.in](http://www.msmedicals.in)

## 8 CORPORATE SOCIAL RESPONSIBILITY POLICY AND RELATED DISCLOSURES/COMPLIANCES

The Company does not cross the threshold limit provided under Section 135 of the Companies Act, 2013 read with the Companies (Corporate Social Responsibility Policy) Rules, 2014 relating to Corporate Social Responsibility, hence CSR is not applicable to the Company.

## 9 RISK MANAGEMENT

The Board has adopted the procedures for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting record, and the timely preparation of reliable financial disclosures.

## 10 INTERNAL FINANCIAL CONTROLS SYSTEM AND THEIR ADEQUACY

The Company has in place adequate systems of internal controls to ensure compliance with policies and procedures, including monitoring procedures to ensure that all assets and investments are safeguarded against loss from unauthorized use or disposition.

## 11 DIRECTORS AND KEY MANAGERIAL PERSONS

During the financial year under review, there were changes in the composition of the Board of Directors.

ARCHNA MANOCHA (DIN: 02020796) resigned from the directorship of the Company with effect from 02.07.2024.

MONA SACHDEVA (DIN: 07220052) resigned from the directorship of the Company with effect from 02.07.2024.

Mr. Sukesh Arora (DIN: 10682240) appointed as an Additional Director of the Company with effect from 02.07.2024 whose appointment was regularised in previous (17<sup>th</sup>) Annual General Meeting

Mr. KARTIK PALTA (DIN: 01543913) appointed as an Additional Director of the Company with effect from 02.07.2024 whose appointment was regularised in previous (17<sup>th</sup>) Annual General Meeting.

The provisions of Section 203 of the Companies Act, 2013 pertaining to appointment of Key Managerial Personnel are not applicable to the Company Particulars of remuneration in terms of Section 197(12) of the Act and Rule 5(2) and (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are applicable to listed public companies. Your Company being a private limited company hence the same has not been provided in the report.

# M S Medicals Pvt. Ltd.

Corporate Office : N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

Tel.: (O) 011-4569 7024 | 4506 7231

Warehouse : C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) Tel.: (O) 011-40574967

E-mail : [info@msmedicals.in](mailto:info@msmedicals.in) / [info1@msmedicals.in](mailto:info1@msmedicals.in) / [yogesh@msmedicals.in](mailto:yogesh@msmedicals.in) / [accounts@msmedicals.in](mailto:accounts@msmedicals.in) | Website : [www.msmedicals.in](http://www.msmedicals.in)



Bridging Service to Life

CIN : U85110DL2008PTC175791

**12 SECRETARIAL AUDIT**

Provisions of Section 204 of the Companies Act, 2013 relating to Secretarial Audit is not applicable to your company.

**13 AUDITOR AND EXPLANATION ON AUDITOR QUALIFICATION:**

Pursuant to the provisions of the section 139 of the Act and the rules framed there under, M/s. RGMG & CO., Chartered Accountants (FRN: 006329N) were appointed as Statutory Auditors of the Company to hold office till the conclusion of AGM of the Company to be held in the year 2029. Auditor's Report for the current financial year is annexed herewith for your kind perusal and information.

The report of the Statutory Auditors along with notes to Schedules is enclosed to this Report. The statutory Auditors report submitted by them does not contain any qualifications, reservations, adverse remarks or disclaimers on the financial statements of the Company for the financial year 2024-2025.

**14 NUMBER OF MEETINGS OF THE BOARD**

8 Meetings of the Board of Directors were held during the year. The meetings were held on 31.05.2024, 13.06.2024, 02.07.2024, 16.07.2024, 24.09.2024, 12.11.2024, 27.01.2025 and 06.03.2025. All the directors of the company attended all the meetings.

**15 DEPOSITS**

The company has not accepted any deposits u/s 73 of Companies Act, 2013 during the year under review.

**16 TRANSFER TO RESERVE**

The Board of Directors does not propose to transfer any profits to any reserve.

**17 SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS**

During the year under review, there were no significant or material orders which were passed by the regulators or courts or tribunals which may impact the going concern status and company's operation in future.

**18 DECLARATION BY INDEPENDENT DIRECTOR**

Provisions of Section 149 relating to Independent Directors is not applicable to your Company, therefore, no statement on declaration to be given by independent directors is being enclosed herewith.

**19 CHANGES IN SHARE CAPITAL**

The paid-up Equity Share Capital as on 31<sup>st</sup> March 2025 was Rs. 95,40,000/. There

## M S Medicals Pvt. Ltd.

**Corporate Office :** N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

**Tel.:** (O) 011-4569 7024 | 4506 7231

**Warehouse :** C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) **Tel.:** (O) 011-40574967

**E-mail :** [info@msmedicals.in](mailto:info@msmedicals.in) / [info1@msmedicals.in](mailto:info1@msmedicals.in) / [yogesh@msmedicals.in](mailto:yogesh@msmedicals.in) / [accounts@msmedicals.in](mailto:accounts@msmedicals.in) | **Website :** [www.msmedicals.in](http://www.msmedicals.in)

was no change in the share capital of the Company during the year under review.

**20 INTER CORPORATE LOANS AND INVESTMENTS**

There was no loans, guarantee and investment made by the Company under section 186 of the Companies Act, 2013 during the year, under review and hence the said provisions are not applicable.

**21 TRANSFER OF UNCLAIMED/UNPAID AMOUNT TO INVESTOR EDUCATION AND PROTECTION FUND**

During the Financial Year 2024-2025, no amount was required to be transferred to the Investor Education and Protection Fund.

**22 PARTICULARS REGARDING CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND EXPENDITURE**

Since the company does not carry out any manufacturing activity, the particulars relating to conservation of energy, technology absorption and other particulars required pursuant to Section 134(3) (m) read with Rule 8 (3) of the Companies (Accounts) Rules, 2014 are not applicable to your Company.

There were foreign exchange earnings and expenditures. Therefore the directors report on the foreign exchange earnings and outgo pursuant to Section 134(3) (m) of the Companies Act, 2013.

**23 WEB LINK OF ANNUAL RETURN**

Pursuant to Section 92(3), Company does not have a Website so there is no requirement to give web link of Annual Return of the Company.

**24 INSTANCES OF FRAUD REPORTED BY THE AUDITORS**

There have been no instances of fraud reported by the Auditors under Section 143(12) of the Act.

**25 MATERNITY COMPLIANCE DISCLOSURE:**

The Company confirms that it has women employees on its rolls during the financial year ended 31st March, 2025. However, no case of maternity benefit arose during the year, and accordingly, no maternity leave, medical benefits, or nursing breaks were availed or provided under the provisions of the Maternity Benefit Act, 1961 during the year under review.

**26 STATUTORY DISCLOSURES**

The directors' responsibility statement as required by section 134(5) of the Companies Act, 2013, reports above.

## M S Medicals Pvt. Ltd.

Corporate Office : N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

Tel.: (O) 011-4569 7024 | 4506 7231

Warehouse : C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) Tel.: (O) 011-40574967

E-mail : [info@msmedicals.in](mailto:info@msmedicals.in) / [info1@msmedicals.in](mailto:info1@msmedicals.in) / [yogesh@msmedicals.in](mailto:yogesh@msmedicals.in) / [accounts@msmedicals.in](mailto:accounts@msmedicals.in) | Website : [www.msmedicals.in](http://www.msmedicals.in)

The provisions of section 148 of the Companies Act, 2013, are not applicable to the Company. Accordingly, there is no requirement of maintenance of cost records as specified under sub-section (1) of section 148 of the Companies Act, 2013.

Pursuant to the legislation 'The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013', the Company has a policy on Prevention of Sexual Harassment at Workplace. During the year under review, no complaint was received from any of the employees,

*Neither any application was made nor any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the financial year.*

*loans were taken from banks or Financial Institutions but there are no disclosure relating to details of difference between the amount of valuation done at the time of one-time settlement and valuation done while taking loan from the Banks or Financial Institutions.*

*Loans and Advances received from Related parties during the year was from owned funds only not from borrowed funds.*

**27 COMPLIANCES OF ALL LAWS**

The Board hereby states that the company has devised proper systems to ensure compliance of all laws applicable to the company.

**28 SECRETARIAL STANDARDS**

The Directors state that the Company has complied with both the applicable Secretarial Standards i.e. SS- 1 and SS-2 relating to 'Meetings of the Board of Directors' and 'General Meetings', respectively.

**29 DISCLOSURE UNDER SEXUAL HARASSMENT OF WOMEN AT THE WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013**

The Company has in place 'Prevention of Sexual Harassment Policy' in line with the requirements of The Sexual Harassment of Women at the Workplace (Prevention, Prohibition & Redressal) Act, 2013. An Internal Complaints Committee (ICC) is in place to redress complaints received regarding sexual harassment.

The following is a summary of sexual harassment complaints received and disposed off during the year,

Number of complaints received: Nil,

Number of complaints disposed off: NA.

## M S Medicals Pvt. Ltd.

**Corporate Office :** N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

**Tel.:** (O) 011-4569 7024 | 4506 7231

**Warehouse :** C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) **Tel.:** (O) 011-40574967

**E-mail :** [info@msmedicals.in](mailto:info@msmedicals.in) / [info1@msmedicals.in](mailto:info1@msmedicals.in) / [yogesh@msmedicals.in](mailto:yogesh@msmedicals.in) / [accounts@msmedicals.in](mailto:accounts@msmedicals.in) | **Website :** [www.msmedicals.in](http://www.msmedicals.in)



Bridging Service to Life

CIN : U85110DL2008PTC175791

30 **APPRECIATION**

Your Directors wish to place on record their sincere appreciation to the shareholders, employees and bankers for their co-operation and support.

For and on the behalf of Board of Directors  
M. S. Medicals Private Limited

  
YOGESH SACHDEVA  
(Director)  
DIN: 00077095

  
SANJAY MANOCHA  
(Director)  
DIN: 00076997

Place: New Delhi  
Date: 16.07.2025

**M S Medicals Pvt. Ltd.**

**Corporate Office :** N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

**Tel.:** (O) 011-4569 7024 | 4506 7231

**Warehouse :** C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) **Tel.:** (O) 011-40574967

**E-mail :** [info@msmedicals.in](mailto:info@msmedicals.in) / [info1@msmedicals.in](mailto:info1@msmedicals.in) / [yogesh@msmedicals.in](mailto:yogesh@msmedicals.in) / [accounts@msmedicals.in](mailto:accounts@msmedicals.in) | **Website :** [www.msmedicals.in](http://www.msmedicals.in)

ANNEXURE-I

FORM NO. AOC-2

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arms length transactions under third proviso thereto

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

01.Details of material contracts or arrangement or transactions at arm's length basis

| S.No | Particulars                                                                                | Details                                                                    |
|------|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| 1    | Name(s) of the related party and nature of relationship                                    | Sceptre Medical Devices Private Limited and related through Director       |
| 2    | Nature of contracts/ arrangements/ transactions                                            | Purchase and Sale of Goods                                                 |
| 3    | Duration of the contracts/ arrangements/ transactions                                      | One Year                                                                   |
| 4    | Salient terms of the contracts or arrangements or transactions including the value, if any | Value of Transactions:<br>Purchase = Rs 4,73,40,243<br>Sale = Rs 41,11,803 |
| 5    | Date of approval by the Board, if any                                                      | 31.05.2024                                                                 |
| 6    | Amount paid as advances, if any                                                            | ---                                                                        |

M S Medicals Pvt. Ltd.

Corporate Office : N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

Tel.: (O) 011-4569 7024 | 4506 7231

Warehouse : C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) Tel.: (O) 011-40574967

E-mail : [info@msmedicals.in](mailto:info@msmedicals.in) / [info1@msmedicals.in](mailto:info1@msmedicals.in) / [yogesh@msmedicals.in](mailto:yogesh@msmedicals.in) / [accounts@msmedicals.in](mailto:accounts@msmedicals.in) | Website : [www.msmedicals.in](http://www.msmedicals.in)

02.Details of material contracts or arrangement or transactions at arm's length basis

| S.No | Particulars                                                                                | Details                                                              |
|------|--------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| 1    | Name(s) of the related party and nature of relationship                                    | Sceptre Medical (India) Private Limited and related through Director |
| 2    | Nature of contracts/ arrangements/ transactions                                            | Purchase and Sale of Goods                                           |
| 3    | Duration of the contracts/ arrangements/ transactions                                      | One Year                                                             |
| 4    | Salient terms of the contracts or arrangements or transactions including the value, if any | Value of Transaction =<br>Purchase : Rs 8,61,22,629<br>Sale: NIL     |
| 5    | Date of approval by the Board, if any                                                      | 31.05.2024                                                           |
| 6    | Amount paid as advances, if any                                                            | ---                                                                  |

03.Details of material contracts or arrangement or transactions at arm's length basis

| S.No | Particulars                                                                                | Details                               |
|------|--------------------------------------------------------------------------------------------|---------------------------------------|
| 1    | Name(s) of the related party and nature of relationship                                    | Mr. Kartik Palta - Director           |
| 2    | Nature of contracts/ arrangements/ transactions                                            | Remuneration                          |
| 3    | Duration of the contracts/ arrangements/ transactions                                      | One Year                              |
| 4    | Salient terms of the contracts or arrangements or transactions including the value, if any | Value of Transactions:<br>Rs 2,10,000 |
| 5    | Date of approval by the Board, if any                                                      | 31.05.2024                            |
| 6    | Amount paid as advances, if any                                                            | ---                                   |

## M S Medicals Pvt. Ltd.

Corporate Office : N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

Tel.: (O) 011-4569 7024 | 4506 7231

Warehouse : C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) Tel.: (O) 011-40574967

E-mail : [info@msmedicals.in](mailto:info@msmedicals.in) / [info1@msmedicals.in](mailto:info1@msmedicals.in) / [yogesh@msmedicals.in](mailto:yogesh@msmedicals.in) / [accounts@msmedicals.in](mailto:accounts@msmedicals.in) | Website : [www.msmedicals.in](http://www.msmedicals.in)

04.Details of material contracts or arrangement or transactions at arm's length basis

| S.No | Particulars                                                                                | Details                                |
|------|--------------------------------------------------------------------------------------------|----------------------------------------|
| 1    | Name(s) of the related party and nature of relationship                                    | Mrs Mona Sachdeva<br>Director Wife     |
| 2    | Nature of contracts/ arrangements/ transactions                                            | Remuneration                           |
| 3    | Duration of the contracts/ arrangements/ transactions                                      | One Year                               |
| 4    | Salient terms of the contracts or arrangements or transactions including the value, if any | Value of Transactions:<br>Rs 12,47,500 |
| 5    | Date of approval by the Board, if any                                                      | 31.05.2024                             |
| 6    | Amount paid as advances, if any                                                            | ---                                    |

5.Details of material contracts or arrangement or transactions at arm's length basis

| S.No | Particulars                                                                                | Details                               |
|------|--------------------------------------------------------------------------------------------|---------------------------------------|
| 1    | Name(s) of the related party and nature of relationship                                    | Mr Yogesh Sachdeva<br>Director        |
| 2    | Nature of contracts/ arrangements/ transactions                                            | Remuneration                          |
| 3    | Duration of the contracts/ arrangements/ transactions                                      | One Year                              |
| 4    | Salient terms of the contracts or arrangements or transactions including the value, if any | Value of Transactions:<br>Rs 9,00,000 |
| 5    | Date of approval by the Board, if any                                                      | 31.05.2024                            |
| 6    | Amount paid as advances, if any                                                            | ---                                   |

## M S Medicals Pvt. Ltd.

Corporate Office : N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

Tel.: (O) 011-4569 7024 | 4506 7231

Warehouse : C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) Tel.: (O) 011-40574967

E-mail : info@msmedicals.in / info1@msmedicals.in / yogesh@msmedicals.in / accounts@msmedicals.in | Website : www.msmedicals.in

6.Details of material contracts or arrangement or transactions at arm's length basis

| S.No | Particulars                                                                                | Details                                |
|------|--------------------------------------------------------------------------------------------|----------------------------------------|
| 1    | Name(s) of the related party and nature of relationship                                    | Manya Sachdeva<br>Director's Daughter  |
| 2    | Nature of contracts/ arrangements/ transactions                                            | Remuneration                           |
| 3    | Duration of the contracts/ arrangements/ transactions                                      | One Year                               |
| 4    | Salient terms of the contracts or arrangements or transactions including the value, if any | Value of Transactions:<br>Rs 13,05,000 |
| 5    | Date of approval by the Board, if any                                                      | 31.05.2024                             |
| 6    | Amount paid as advances, if any                                                            | ---                                    |

7.Details of material contracts or arrangement or transactions at arm's length basis

| S.No | Particulars                                                                                | Details                               |
|------|--------------------------------------------------------------------------------------------|---------------------------------------|
| 1    | Name(s) of the related party and nature of relationship                                    | Sukesh Arora<br>Director              |
| 2    | Nature of contracts/ arrangements/ transactions                                            | Remuneration                          |
| 3    | Duration of the contracts/ arrangements/ transactions                                      | One Year                              |
| 4    | Salient terms of the contracts or arrangements or transactions including the value, if any | Value of Transactions:<br>Rs 8,80,000 |
| 5    | Date of approval by the Board, if any                                                      | 31.05.2024                            |
| 6    | Amount paid as advances, if any                                                            | ---                                   |

## M S Medicals Pvt. Ltd.

Corporate Office : N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

Tel.: (O) 011-4569 7024 | 4506 7231

Warehouse : C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) Tel.: (O) 011-40574967

E-mail : [info@msmedicals.in](mailto:info@msmedicals.in) / [info1@msmedicals.in](mailto:info1@msmedicals.in) / [yogesh@msmedicals.in](mailto:yogesh@msmedicals.in) / [accounts@msmedicals.in](mailto:accounts@msmedicals.in) | Website : [www.msmedicals.in](http://www.msmedicals.in)



Bridging Service to Life

CIN : U85110DL2008PTC175791

8.Details of material contracts or arrangement or transactions at arm's length basis

| S.No | Particulars                                                                                | Details                               |
|------|--------------------------------------------------------------------------------------------|---------------------------------------|
| 1    | Name(s) of the related party and nature of relationship                                    | Archna Manocha<br>Director Wife       |
| 2    | Nature of contracts/ arrangements/ transactions                                            | Rent                                  |
| 3    | Duration of the contracts/ arrangements/ transactions                                      | One Year                              |
| 4    | Salient terms of the contracts or arrangements or transactions including the value, if any | Value of Transactions:<br>Rs 2,56,500 |
| 5    | Date of approval by the Board, if any                                                      | 31.05.2024                            |
| 6    | Amount paid as advances, if any                                                            | ----                                  |

9.Details of material contracts or arrangement or transactions at arm's length basis

| S.No | Particulars                                                                                | Details                             |
|------|--------------------------------------------------------------------------------------------|-------------------------------------|
| 1    | Name(s) of the related party and nature of relationship                                    | Mona Sachdeva<br>Director Wife      |
| 2    | Nature of contracts/ arrangements/ transactions                                            | Rent                                |
| 3    | Duration of the contracts/ arrangements/ transactions                                      | One Year                            |
| 4    | Salient terms of the contracts or arrangements or transactions including the value, if any | Value of Transactions:<br>Rs 256500 |
| 5    | Date of approval by the Board, if any                                                      | 31.05.2024                          |
| 6    | Amount paid as advances, if any                                                            | ----                                |

For and on the behalf of Board of Directors  
M S Medicals Private Limited

  
Yogesh Sachdeva  
Director  
DIN: 00077095  
Place: New Delhi  
Date: 16-07-2025

**M S Medicals Pvt. Ltd.**

**Corporate Office :** N-1 | Lower Ground | Satyawati Colony | Ashok Vihar Phase-III | Delhi-110 052 (INDIA)

**Tel.:** (O) 011-4569 7024 | 4506 7231

**Warehouse :** C-17/1 | Ground Floor | Wazirpur Industrial Area | New Delhi-110 052 | (INDIA) **Tel.:** (O) 011-40574967

**E-mail :** info@msmedicals.in / info1@msmedicals.in / yogesh@msmedicals.in / accounts@msmedicals.in | **Website :** www.msmedicals.in